Prostate-specific membrane antigen (PSMA), also known as glutamic acid carboxypeptidase II, is a type II transmembrane glycoprotein and an ideal target for the treatment of PCa [6,7,8]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.